EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort

Kevin Windirsch, Suzana Jordan, Mike Oliver Becker, Cosimo Bruni, Rucsandra Dobrota, Muriel Elhai, Ion-Alexandru Garaiman, Carmen-Marina Mihai, Michele Iudici, Paul Hasler, Camillo Ribi, Britta Maurer und 3 weitere

Swiss Medical Weekly · 2024

DOI: 10.57187/s.3630 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Kevin Windirsch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Lung Diseases, Interstitial, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations. METHODS: Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry. Patients fulfilling the 2013 ACR/EULAR systemic sclerosis classification criteria at baseline were included. To determine the differences in treatment of varying degrees of fibrosis, four groups were identified: (1) patients with a modified Rodnan skin score (mRSS) >0; (2) those with mRSS ≥7; (3) those with interstitial lung disease (SSc-ILD), diagnosed by either chest X-Ray or high-resolution computed tomography; and (4) patients fulfilling one of the additional criteria for extensive interstitial lung disease, defined as interstitial lung disease involvement of >20% in high-resolution computed tomography, dyspnea NYHA-stage 3/4, or a predicted forced vital capacity (FVC) of 0, of whom 195 (33.1%) had mRSS ≥7; interstitial lung disease was diagnosed in 198 of 456 (43.4%), of whom 106 (18.0 %) showed extensive interstitial lung disease. Regarding non-biologic disease-modifying medications (DMARDs), the most frequently prescribed was methotrexate, followed by hydroxychloroquine and mycophenolate mofetil. Rituximab and tocilizumab were most frequently used among the biologic DMARDs. Specifically, 148/372 (39.8%) of treated patients with skin fibrosis received methotrexate, mycophenolate mofetil or rituximab, and 80/177 (45.2%) with interstitial lung disease received cyclophosphamide, mycophenolate mofetil, tocilizumab or rituximab. Most patients received a proton-pump inhibitor, and few patients underwent hematopoietic stem cell transplantation. CONCLUSION: Overall, in Switzerland, a wide range of medications is prescribed for systemic sclerosis patients. This includes modern, targeted treatments for which randomised controlled clinical trial have been recently reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicLung Diseases, InterstitialAntirheumatic AgentsHumansImmunosuppressive AgentsRituximabMethotrexateMycophenolic AcidProspective StudiesSwitzerlandFibrosis

Substanzen

Immunosuppressive AgentsRituximabMethotrexateMycophenolic AcidAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Division of Rheumatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
  • Department of Rheumatology,Kantonsspital Aarau, Aarau, Switzerland.
  • Department of Clinical Immunology and Allergy, Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland.
  • Department of Rheumatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Marche Polytechnic University, Institute of Clinical Medicine, University of Ancona, Ancona, Italy.

Zitieren

APA

Windirsch, K., Jordan, S., Becker, M. O., Bruni, C., Dobrota, R., Elhai, M., Garaiman, I. A., Mihai, C. M., Iudici, M., Hasler, P., Ribi, C., Maurer, B., Gabrielli, A., Hoffmann-Vold, A. M., & Distler, O. (2024). Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort. Swiss Medical Weekly. https://doi.org/10.57187/s.3630

Vancouver

Windirsch K, Jordan S, Becker MO, Bruni C, Dobrota R, Elhai M, et al. Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort. Swiss Medical Weekly. 2024. doi:10.57187/s.3630

BibTeX
@article{Windirsch2024,
  author = {Windirsch, Kevin and Jordan, Suzana and Becker, Mike Oliver and Bruni, Cosimo and Dobrota, Rucsandra and Elhai, Muriel and Garaiman, Ion-Alexandru and Mihai, Carmen-Marina and Iudici, Michele and Hasler, Paul and Ribi, Camillo and Maurer, Britta and Gabrielli, Armando and Hoffmann-Vold, Anna-Maria and Distler, Oliver},
  title = {Therapeutic management of fibrosis in systemic sclerosis patients – an analysis from the Swiss EUSTAR cohort},
  journal = {Swiss Medical Weekly},
  year = {2024},
  doi = {10.57187/s.3630}
}
Kostenlos starten →